Results for: Chemotherapies

Eli Lilly analysis leads to introduction of new vial size.

A new analysis reviews several analyses of differential costs of care provided in the doctors’ offices and hospital outpatient settings.

New analysis in BMJ looks at avoidable excess medicine and waste in top 20 U.S. cancer drugs and how to prevent it

Oral anticancer agents are being launched at significantly higher prices compared with a decade ago and has become a barrier for some patients.

AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016 kicked off by delving into the near-term specialty pharmaceutical pipeline

An analysis on why proposed changes to the system are being met with opposition and the impact for providers and patients.

There is growing outrage over the billions of expensive drugs being thrown away simply due to one-size-fits-all packaging.

In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States.

Dr. David Pfister of Memorial Sloan Kettering Cancer Center summarizes the work that Dr. Bach and colleagues regarding the high cost of cancer treatments and alternative pricing methods.

Drs. Rena Conti and Peter Bach report on the unintended consequences of the 340B drug discount program.

In this study, Dr. Bach and coauthors find that patent-protected chemotherapies are used approximately 30% of the time for for off-label indications.

MSK physicians, including Dr. Bach, announce their refusal to offer a cancer drug to patients because of its "phenomenally expensive" cost.